Published in Neuropsychopharmacology on January 01, 2012
Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review. Pharmacol Ther (2013) 2.64
SMA-MAP: a plasma protein panel for spinal muscular atrophy. PLoS One (2013) 0.82
The potential of 12/15-lipoxygenase inhibitors in stroke therapy. Future Med Chem (2014) 0.79
Reengineering translational science: the time is right. Sci Transl Med (2011) 7.55
NIH Molecular Libraries Initiative. Science (2004) 7.04
The challenge of translational research--a perspective from the NINDS. Nat Neurosci (2002) 1.23
Mitochondrial encephalopathy, lactic acidosis, and strokelike episodes: basic concepts, clinical phenotype, and therapeutic management of MELAS syndrome. Ann N Y Acad Sci (2008) 2.39
The motor neuron response to SMN1 deficiency in spinal muscular atrophy. Muscle Nerve (2014) 2.02
Varying loads of the mitochondrial DNA A3243G mutation in different tissues: implications for diagnosis. Am J Med Genet A (2004) 1.64
Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2010) 1.45
Experience with the Awaji Island modifications to the ALS diagnostic criteria. Muscle Nerve (2010) 1.43
Validation of the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND). Pediatr Phys Ther (2011) 1.42
Wolff-Parkinson-White syndrome in Patients With MELAS. Arch Neurol (2007) 1.29
Missed opportunities for duchenne muscular dystrophy. J Pediatr (2009) 1.21
Common data elements for clinical research in Friedreich's ataxia. Mov Disord (2012) 1.14
Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study. PLoS One (2012) 1.08
Validation of the Expanded Hammersmith Functional Motor Scale in spinal muscular atrophy type II and III. J Child Neurol (2011) 1.08
Hypocitrullinemia in patients with MELAS: an insight into the "MELAS paradox". J Neurol Sci (2004) 1.07
Association of autistic spectrum disorders with dystrophinopathies. Pediatr Neurol (2009) 1.07
Association of plastin 3 expression with disease severity in spinal muscular atrophy only in postpubertal females. Arch Neurol (2010) 1.06
Spinal muscular atrophy. Neurotherapeutics (2008) 1.06
Novel mitochondrial DNA ND5 mutation in a patient with clinical features of MELAS and MERRF. Arch Neurol (2005) 1.03
Carrier testing for spinal muscular atrophy. Genet Med (2010) 1.02
Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol (2005) 1.01
Increased fat mass and high incidence of overweight despite low body mass index in patients with spinal muscular atrophy. Neuromuscul Disord (2009) 1.01
Candidate proteins, metabolites and transcripts in the Biomarkers for Spinal Muscular Atrophy (BforSMA) clinical study. PLoS One (2012) 0.95
Cerebral metabolic abnormalities in A3243G mitochondrial DNA mutation carriers. Neurology (2014) 0.94
Efficiency perspectives on adaptive designs in stroke clinical trials. Stroke (2011) 0.94
Scoliosis surgery in children with neuromuscular disease: findings from the US National Inpatient Sample, 1997 to 2003. Arch Neurol (2010) 0.94
Body mass index (BMI) as predictor of ALSFRS-R score decline in ALS patients. Amyotroph Lateral Scler Frontotemporal Degener (2013) 0.93
Clinical features and genetics of myoclonic epilepsy with ragged red fibers. Adv Neurol (2002) 0.88
Clinical outcome measures in spinal muscular atrophy. J Child Neurol (2009) 0.88
Longitudinal changes of mtDNA A3243G mutation load and level of functioning in MELAS. Am J Med Genet A (2009) 0.88
A pathogenic peripherin gene mutation in a patient with amyotrophic lateral sclerosis. Brain Pathol (2004) 0.87
Therapeutic developments in spinal muscular atrophy. Ther Adv Neurol Disord (2010) 0.87
Adiposity is increased among high-functioning, non-ambulatory patients with spinal muscular atrophy. Neuromuscul Disord (2010) 0.87
The National Institutes of Health Blueprint for Neuroscience Research. J Neurosci (2006) 0.87
Muscle volume estimation by magnetic resonance imaging in spinal muscular atrophy. J Child Neurol (2010) 0.86
Infrastructure resources for clinical research in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener (2013) 0.85
Thigh muscle volume measured by magnetic resonance imaging is stable over a 6-month interval in spinal muscular atrophy. J Child Neurol (2011) 0.85
Down syndrome: national conference on patient registries, research databases, and biobanks. Mol Genet Metab (2011) 0.85
Amyotrophic lateral sclerosis and primary lateral sclerosis: evidence-based diagnostic evaluation of the upper motor neuron. Neuroimaging Clin N Am (2003) 0.83
Amyotrophic lateral sclerosis: an emerging era of collaborative gene discovery. PLoS One (2007) 0.83
Autonomic symptoms in carriers of the m.3243A>G mitochondrial DNA mutation. Arch Neurol (2010) 0.83
Reliability of telephone administration of the PedsQL Generic Quality of Life Inventory and Neuromuscular Module in spinal muscular atrophy (SMA). Neuromuscul Disord (2010) 0.82
SMA-MAP: a plasma protein panel for spinal muscular atrophy. PLoS One (2013) 0.82
A novel tRNA(Val) mitochondrial DNA mutation causing MELAS. J Neurol Sci (2008) 0.81
Web-based data management for a phase II clinical trial in ALS. Amyotroph Lateral Scler (2009) 0.81
Age at disease onset predicts likelihood and rapidity of growth failure among infants and young children with spinal muscular atrophy types 1 and 2. J Child Neurol (2012) 0.81
Independent mobility after early introduction of a power wheelchair in spinal muscular atrophy. J Child Neurol (2012) 0.81
Learning to walk: challenges for spinal muscular atrophy clinical trials. Neurology (2007) 0.79
Bioelectrical impedance analysis can be a useful screen for excess adiposity in spinal muscular atrophy. J Child Neurol (2010) 0.78
Commonalities and challenges in the development of clinical trial measures in neurology. Neurotherapeutics (2015) 0.78
Motor Unit Estimate Number in the Anterior Tibial Muscle: Normative Data versus Findings in Critically Ill Patients in Intensive Care Units. J Clin Neuromuscul Dis (2002) 0.77
Randomized control trials in ALS: lessons learned. Amyotroph Lateral Scler Other Motor Neuron Disord (2004) 0.77
ALS Research Group (ALSRG): second meeting, a summary report. Amyotroph Lateral Scler (2006) 0.77
Carotid intervention: is it warranted in asymptomatic individuals if risk factors are aggressively managed? Stroke (2014) 0.76
Fatigue leads to gait changes in spinal muscular atrophy. Muscle Nerve (2011) 0.76
Reply: To PMID 23893312. Muscle Nerve (2014) 0.75
Survival in SMA type 1. Neuromuscul Disord (2008) 0.75
Strength, Hardening, and Failure Observed by In Situ TEM Tensile Testing. Adv Eng Mater (2012) 0.75
ALS treatment strikes out while trying for a homer: the topiramate trial. Neurology (2003) 0.75
Funding agencies and disease organizations: resources and recommendations to facilitate ALS clinical research. Amyotroph Lateral Scler Frontotemporal Degener (2013) 0.75
A 14-year-old male with asymptomatic proteinuria and hearing loss. Am J Kidney Dis (2003) 0.75
Adding more muscle and nerve to clinical trials. Muscle Nerve (2011) 0.75
Erratum to: Commonalities and Challenges in the Development of Clinical Trial Measures in Neurology. Neurotherapeutics (2015) 0.75
Small-Fiber Neuropathy Associated with Capecitabine (Xeloda)-induced Hand-foot Syndrome: A Case Report. J Clin Neuromuscul Dis (2006) 0.75
Design and evaluation of a hybrid passive and active gravity neutral orthosis (GNO). Conf Proc IEEE Eng Med Biol Soc (2009) 0.75
Clinical and biochemical heterogeneity in an Italian family with CPT II deficiency due to Ser 113 Leu mutation. Can J Neurol Sci (2005) 0.75
An integrated motion capture system for evaluation of neuromuscular disease patients. Conf Proc IEEE Eng Med Biol Soc (2009) 0.75